GlaxoSmithKline Pakistan Limited GLAXO
Rs 350.00
Vol86,849Updated10:3029 Jul 2026
01—At a Glance
The headline take on GLAXO — valuation, income, returns, and efficiency
Consolidated snapshot
02—Price & Performance
Closing prices across timeframes, returns, and range context
GLAXO — Price History
Daily closing series · toggle period below
03—Key Metrics
Valuation, profitability, structure, and risk in one grid
04—Dividend History & Yield
Payout track record, yield trend, and upcoming distribution
GLAXO has paid Rs 17.00 per share in cash dividends over the trailing 12 months — a 4.9% yield at the last close. Its most recent payout was Rs 12.00/share, announced 26 Mar 2026 with book closure from 23 Apr 2026. Annual dividend-per-share history back to 2016 is charted below.
Latest Payout
Dividend Per Share Trend
Payout History
Source: PSX company payouts
| Announced | For Period | Type | Amount | Book Closure |
|---|---|---|---|---|
| 26 Mar 2026 | 31 Dec 2025 (YR) | Cash | Rs 12.00(120%) | 23 Apr 2026 – 30 Apr 2026 |
| 26 Aug 2025 | 30 Jun 2025 (HYR) | Cash | Rs 5.00(50%) | 09 Sept 2025 – 11 Sept 2025 |
| 24 Mar 2025 | 31 Dec 2024 (YR) | Cash | Rs 10.00(100%) | 22 Apr 2025 – 28 Apr 2025 |
05—Financials & Earnings
Income, balance sheet, and key ratios from published accounts
GLAXO's market capitalisation stands at Rs 111.46B as of 29 Jul 2026 — down 11.2% over the past 12 months (from Rs 125.46B).
Financial Statements
How OGDC's income and balance sheet have evolved
| PKR Millions | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | Trend |
|---|---|---|---|---|---|---|---|
| Net Sales / Revenue | 65,901 | 61,188 | 49,661 | 41,842 | 36,661 | 35,090 | |
| Cost of Sales | 41,517 | 45,800 | 46,158 | 34,560 | 26,924 | 27,556 | |
| Gross Profit | 24,384 | 15,388 | 3,503 | 7,282 | 9,737 | 7,534 | |
| Administrative Expenses | 1,958 | 1,799 | 1,811 | 1,419 | 1,072 | 1,332 | |
| Operating Profit | 16,899 | 8,873 | -3,333 | 1,997 | 5,680 | 3,436 | |
| EBITDA | 18,314 | 10,028 | -2,395 | 2,874 | 6,471 | 4,228 | |
| Other Income | 1,414 | 2,833 | 5,764 | 4,255 | 2,554 | 1,977 | |
| Financial Charges | 168 | 313 | 63 | 716 | 164 | 84 | |
| Profit Before Tax | 16,683 | 10,476 | 2,177 | 5,106 | 7,424 | 4,903 | |
| Taxation | 6,658 | 3,940 | 1,643 | 2,643 | 2,070 | 1,527 | |
| Profit After Tax | 10,025 | 6,536 | 534 | 2,463 | 5,354 | 3,376 | |
| EPS - Basic (Rs) | Rs 31.48 | Rs 20.52 | Rs 1.68 | Rs 7.73 | Rs 16.81 | Rs 10.60 |
All figures in PKR millions from published accounts.
Profitability & Returns
Margins, returns on capital, and earnings per share
Latest · FY25
| Ratio | Value |
|---|---|
| Net profit margin | 15.2% |
| Gross profit margin | 37.0% |
| EBITDA margin | 27.8% |
| EBIT margin | 25.6% |
Net profit margin
Net profit ÷ revenue · %
Financial Health
Coverage, leverage, and the strength of the balance sheet
Latest · FY25
| Ratio | Value |
|---|---|
| Effective tax rate | 39.9% |
Effective tax rate
Taxation ÷ profit before tax · %
Market cap trajectory
Close × current shares outstanding · current Rs 111.46B
Valuation & Capital Returns
What the market is paying for GLAXO, and what it returns to shareholders
Latest · FY25
| Ratio | Value |
|---|---|
| Price to earnings | 12.38x |
| Price to sales | 1.88x |
Price to earnings
Period-end price ÷ EPS · times
06—Technical Analysis
Trading signal, moving averages, momentum, and key levels
10-day SMA (Rs 351.75) is below the 30-day SMA (Rs 364.81). RSI at 44 sits in the neutral band.
Moving AverageThe average close over a set window (10/30/200 days) — smooths daily noise to reveal the trend.Read the full guide →
| Period | Value | vs Current | Position |
|---|---|---|---|
| SMA 10 | Rs 351.75 | +0.50% | Below |
| SMA 30 | Rs 364.81 | +4.23% | Below |
| SMA 60 | Rs 356.92 | +1.98% | Below |
| SMA 200 | Rs 378.25 | +8.07% | Below |
At 44, momentum sits within the neutral band (30–70), suggesting balanced buying and selling pressure.
- MACD-4.03
- Signal-2.63
- Histogram-1.40
07—Leverage Insights
MTS, margin financing, futures open interest, and combined exposure
Leverage Composition
MTS · MFS stacked over the selected window
As of 16 Jul 2026
No blank sales
No net blank (short) sales reported for GLAXO on the latest PSX DFC report.
08—Settlement Insights
UIN-wise settlement concentration and price context
Metrics and charts over the selected trailing window
Settlement % Trajectory
Solid = UIN settlement % · Dashed = 14-session EMA
As of 16 Jul 2026
Price vs Settlement
Close price (left axis) · UIN settlement % (right axis)
10—About the Company
Business description, governance, and corporate information
GlaxoSmithKline Pakistan Limited is incorporated in Pakistan as a limited liability company. It is engaged in manufacturing and marketing of research based ethical specialties and pharmaceutical products. The Company is a subsidiary of S.R. One International B.V., incorporated in Netherlands, whereas its ultimate parent company is GlaxoSmithKline plc, UK (GSK plc).
Corporate Information
- RegistrarCDC Share Registrar Services Limited CDC House, 99 - B, Block - B S.M.C.H.S., Main Shahra-e-Faisal Karachi
- AuditorYousuf Adil, Chartered Accountants
- Websitewww.pk.gsk.com
- Address35 - Dockyard Road, West Wharf, Karachi
- SectorPharmaceuticals
- Financial Year EndDecember
Key People
| Name | Role |
|---|---|
ESErum Shakir Rahim | CEO |
DODmytro Oliinyk | Chairperson |
HMHina Mir | Company Secretary |
Reports & Filings
- Quarterly Report — 31 Mar 2026PDF
- Quarterly Report — 30 Sept 2025PDF
- Quarterly Report — 30 Jun 2025PDF
- Quarterly Report — 31 Mar 2025PDF
- Annual Report FY2025PDF
- Quarterly Report — 31 Mar 2024PDF
- Annual Report FY2024PDF
- Quarterly Report — 30 Sept 2023PDF
Sourced from official PSX financial-report submissions.
11—Recent Announcements
Latest company filings as reported on PSX
Filings and disclosures from the PSX announcement feed
- 08 Jun 2026Others
- 01 Jun 2026Others
- 25 May 2026Others
- 08 May 2026Others
- 06 May 2026Dividend
- 30 Apr 2026Corporate Briefing
- 30 Apr 2026Board Meetings
- 29 Apr 2026Financial Results
12—Peers in Pharmaceuticals
How the cohort is moving — same-sector stocks by market cap
GLAXO vs Pharmaceuticals sector median
| Metric | GLAXO | Sector median |
|---|---|---|
| P/E RatioShare price ÷ earnings per share — the price you pay for each rupee of annual profit. Compare within a sector.Read the full guide → | 11.1x | 16.0x |
| Dividend YieldTrailing-12-month cash dividends ÷ share price. A high yield can signal income — or a falling price.Read the full guide → | 4.9% | 4.0% |
| Return on EquityNet profit ÷ shareholders' equity — how hard the company works each rupee investors have put in.Read the full guide → | 32.4% | 22.3% |
| 1-Year Return | -10.5% | -8.7% |
| Market CapitalisationShare price × total shares — the company's full market value, and the basis for index weightings.Read the full guide → | Rs 111.46B | Rs 27.79B |
Pharmaceuticals · sector heat
13—Frequently Asked Questions
The most common questions investors ask about GLAXO
Frequently Asked Questions
GLAXO closed at Rs 350.00 on 29 Jul 2026, down 1.26% on the day, within a 52-week range of Rs 293.09–459.94. Prices on this page refresh through the trading day; log in to BSL for live quotes.
Yes — GSK Pakistan refers to GlaxoSmithKline Pakistan Limited, which trades on the Pakistan Stock Exchange under the ticker GLAXO. This page covers the live GLAXO share price, dividends, financials, and company information.
GlaxoSmithKline Pakistan Limited is incorporated in Pakistan as a limited liability company. See About the Company on this page for the full profile, management, and corporate information.
GLAXO has paid Rs 17.00 per share in cash dividends over the trailing 12 months — a 4.9% yield at the last close. Review the payout history in the Dividends section and compare with the highest dividend yield stocks on PSX.
No upcoming payout is announced yet. The most recent was a payout of Rs 12.00 per share with book closure from 23 Apr 2026. New announcements appear on this page and on the PSX ex-dates calendar.
Yes — GlaxoSmithKline Pakistan Limited is on the PSX's Shariah-compliant (KMI All Shares) list and also belongs to the KSE-100. Browse all Shariah-compliant PSX stocks.
GLAXO trades at 11.1x earnings against a Pharmaceuticals median of 16.0x, with a 4.9% dividend yield versus 4.0%. The full comparison table and peer list are in the Peers section, or explore the Pharmaceuticals sector page.
Annual reports from FY2024 to FY2025 are linked under Reports & Filings in the About section of this page, sourced from official PSX submissions.
Open a BSL trading account, fund it, and place your GLAXO order on the Pakistan Stock Exchange — account opening takes minutes online, with PSX execution, research, and concierge support included.
Quotes and metrics refresh on a regular cadence through the trading day and after the close. For streaming real-time PSX prices and order placement, log in to your BSL account.
Ready to invest in GLAXO?
Open a BSL trading account in under 10 minutes
Buy and sell GLAXO and 550+ other PSX-listed stocks with low commissions, real-time data, and a concierge research desk backing every trade.